Compare Nomura Holdings Inc (NMR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Sanofi SA — how do they compare? Nomura Holdings Inc trades at $10.74 (market cap $30.77B), while Sanofi SA trades at $42.95 (market cap $103.41B). The key difference: Sanofi SA is far larger — about 3.4× Nomura Holdings Inc's market cap, and Sanofi SA pays the higher dividend (5.65%). Which is the better fit depends on your goals.
| NMR | SNY | |
|---|---|---|
Market Cap | $30.77B | $103.41B |
Sector | Financials | Health |
52-Week High | $10.65 | $52.34 |
52-Week Low | $6.73 | $41.33 |
Dividend Yield | 3.1% | 5.65% |
Enterprise Value | — | $123.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $10.63, showing a slight 0.19% decline. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Revenue surged to $1.66 trillion in 2025, with net income reaching $340.74 billion and a robust 20.4% margin. Recent earnings beat expectations in Q2 2026, but missed in prior quarters. Analyst sentiment is mixed with a 'Hold' consensus, while news highlights momentum in wholesale and wealth management segments.
Outlook remains cautiously optimistic due to solid profitability and growth, but risks include volatile cash flows, high debt levels, and competitive pressures. The stock's valuation at a P/E of 12.46 appears reasonable, yet investor caution is warranted given earnings inconsistencies and macroeconomic uncertainties affecting financial stocks.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
